Skip to content

Annexon ANNX Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Vera Therapeutics logo
Vera TherapeuticsVERA
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Glaukos logo
GlaukosGKOS

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's operating lease right-of-use asset amortization?
Annexon (ANNX) reported operating lease right-of-use asset amortization of $418K in Q1 2026.
How has Annexon's operating lease right-of-use asset amortization changed year-over-year?
Annexon's operating lease right-of-use asset amortization increased by 16.4% year-over-year, from $359K to $418K.
What is the long-term trend for Annexon's operating lease right-of-use asset amortization?
Over 4 years (2021 to 2025), Annexon's operating lease right-of-use asset amortization has grown at a 4.5% compound annual growth rate (CAGR), from $1.27M to $1.52M.